Personalized medicine in rheumatoid arthritis: methotrexate polyglutamylation revisited

References

• Bertino JR. Karnofsky memorial lecture. Ode to methotrexate. J Clin Oncol. 1993 Jan;11(1):5–14. PubMed PMID: 8418242.
   PubMedGoogle Scholar
• Brown PM, Pratt AG, Isaacs JD. Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat Rev Rheumatol. 2016 Dec;12(12):731–742. PubMed PMID: 27784891.
   PubMed Web of Science ®Google Scholar
• Bulatovic M, Heijstek MW, Van Dijkhuizen EH, et al. Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis. Ann Rheum Dis. 2012 Sep;71(9):1484–1489. PubMed PMID: 22473625.
   PubMed Web of Science ®Google Scholar
• van der Heijden JW, Dijkmans BA, Scheper RJ, et al. Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs–from bench to bedside. Nat Clin Pract Rheumatol. 2007 Jan;3(1):26–34. PubMed PMID: 17203006.
   PubMedGoogle Scholar
• Raz S, Stark M, Assaraf YG. Folylpoly-gamma-glutamate synthetase: a key determinant of folate homeostasis and antifolate resistance in cancer. Drug Resist Updat. 2016 Sep;28:43–64. PubMed PMID: 27620954.
   PubMed Web of Science ®Google Scholar
• Assaraf YG. Molecular basis of antifolate resistance. Cancer Metastasis Rev. 2007 Mar;26(1):153–181. PubMed PMID: 17333344.
   PubMed Web of Science ®Google Scholar
• Cronstein BN, Sitkovsky M. Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases. Nat Rev Rheumatol. 2017 Jan;13(1):41–51. PubMed PMID: 27829671; PubMed Central PMCID: PMC5173391.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017 Jun;76(6):960–977. PubMed PMID: 28264816.
   PubMed Web of Science ®Google Scholar
• Rohr MK, Mikuls TR, Cohen SB, et al. Underuse of methotrexate in the treatment of rheumatoid arthritis: a national analysis of prescribing practices in the US. Arthritis Care Res (Hoboken). 2017 Jun;69(6):794–800. PubMed PMID: 27863180.
   PubMed Web of Science ®Google Scholar
• Wessels JA, de Vries-Bouwstra JK, Heijmans BT, et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum. 2006 Apr;54(4):1087–1095. PubMed PMID: 16572443.
   PubMedGoogle Scholar
• Wessels JA, van der Kooij SM, le Cessie S, et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum. 2007 Jun;56(6):1765–1775. PubMed PMID: 17530705.
   PubMed Web of Science ®Google Scholar
• Stamp LK, Roberts RL. Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases. Pharmacogenomics. 2011 Oct;12(10):1449–1463. PubMed PMID: 22008049.
   PubMed Web of Science ®Google Scholar
• Dervieux T, Wessels JA, Kremer JM, et al. Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritis. Pharmacogenet Genomics. 2012 Jan;22(1):1–9. PubMed PMID: 22044941.
   PubMed Web of Science ®Google Scholar
• Hoekstra M, Haagsma C, Neef C, et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol. 2004 Apr;31(4):645–648. PubMed PMID: 15088287.
   PubMed Web of Science ®Google Scholar
• Dervieux T, Furst D, Lein DO, et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis. 2005 Aug;64(8):1180–1185. PubMed PMID: 15677700; PubMed Central PMCID: PMCPMC1755602.
   PubMed Web of Science ®Google Scholar
• Stamp LK, O’Donnell JL, Chapman PT, et al. Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy. Arthritis Rheum. 2010 Feb;62(2):359–368. PubMed PMID: 20112376.
   PubMedGoogle Scholar
• de Rotte MC, den Boer E, de Jong PH, et al. Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis. Ann Rheum Dis. 2015 Feb;74(2):408–414. PubMed PMID: 24297383.
   PubMed Web of Science ®Google Scholar
• Calasan MB, den Boer E, de Rotte MC, et al. Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in juvenile idiopathic arthritis patients. Ann Rheum Dis. 2015 Feb;74(2):402–407. PubMed PMID: 24288013.
   PubMed Web of Science ®Google Scholar
• Takahashi C, Kaneko Y, Okano Y, et al. Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study. RMD Open. 2017;3(1):e000363.
   PubMed Web of Science ®Google Scholar
• den Boer E, de Rotte MC, Pluijm SM, et al. Determinants of erythrocyte methotrexate polyglutamate levels in rheumatoid arthritis. J Rheumatol. 2014 Nov;41(11):2167–2178. PubMed PMID: 25225283.
   PubMed Web of Science ®Google Scholar
• den Boer E, Meesters RJ, van Zelst BD, et al. Measuring methotrexate polyglutamates in red blood cells: a new LC-MS/MS-based method. Anal Bioanal Chem. 2013 Feb;405(5):1673–1681. PubMed PMID: 23239179.
   PubMed Web of Science ®Google Scholar
• Muller IB, Heydari P, Lin M, et al. AB0236 Development and validation of a sensitive lc-ms/ms-based method for analysis of enzymatic activity of folylpolyglutamate synthetase and methotrexate polyglutamates in peripheral blood mononuclear cells of rheumatoid arthritis patients. Ann Rheum Dis. 2018;77:1300.
   Web of Science ®Google Scholar
• Rots MG, Pieters R, Peters GJ, et al. Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia. Blood. 1999 Mar 1;93(5):1677–1683. PubMed PMID: 10029597.
   PubMed Web of Science ®Google Scholar
• Wojtuszkiewicz A, Assaraf YG, Hoekstra M, et al. The association of aberrant folylpolyglutamate synthetase splicing with ex vivo methotrexate resistance and clinical outcome in childhood acute lymphoblastic leukemia. Haematologica. 2016 Jul;101(7):e291–4. PubMed PMID: 27036162; PubMed Central PMCID: PMC5004475.
   PubMed Web of Science ®Google Scholar
• van der Wilt CL, Cloos J, de Jong M, et al. Screening of colon tumor cells and tissues for folylpolyglutamate synthetase activity. Oncol Res. 1995;7(6):317–321. PubMed PMID: 8527866.
   PubMed Web of Science ®Google Scholar